Conatus Pharmaceuticals (CNAT) PT Lowered to $10 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
December 6, 2018 9:16 AM ESTH.C. Wainwright analyst Ed Arce lowered the price target on Conatus Pharmaceuticals (NASDAQ: CNAT) to $14.00 (from $15.00) while maintaining a Buy rating.
Arce commented, "We fully expect CNAT shares to drop over 10% today as some investors will undoubtedly look no further at yesterday's release of the ENCORE-PH top-line results, than to see that the study missed its primary endpoint. Following this expected initial... More
